News Releases

2020

Information in this news release was current as of the original release date.

Otsuka Pharmaceutical's news releases are intended to provide information to the media. It may contain information about ethical drugs or products under development, however information contained in the news releases are not intended to constitute promotion, advertisement, or medical advice.

December

2020

Formation of a Licensing Agreement Covering Japan and Europe for the Lupus Nephritis Drug "Voclosporin"

Otsuka Pharmaceutical Signs On as "B. League Supporting Company" -To cooperate with physical conditioning and regional healthcare-related initiatives-

UL·OS Medicated Scalp Shampoo and Medicated Skin Wash to Appear in New Packaging

Quick NaviTM Rapid Diagnostic Test in Japan Now Supports Simultaneous Testing for Influenza and COVID-19 Through Collection of a Single Testing Sample

Debut of InnerSignal Skin Care Brand Outside Japan - Launched in South Korea as Functional Cosmetics with Two Key Benefits -

Otsuka and its subsidiary Astex announce results of phase 3, ASTRAL-2 and ASTRAL-3 trials of guadecitabine in patients with previously treated AML and MDS/CMML

Positive Top-Line Results in Phase 3 Trial of OPC-61815, a V2 -Receptor Antagonist for the Treatment of Cardiac Edema

Quick NaviTM-COVID 19 Ag Rapid Diagnostic Test in Japan Now Enables Test Sample Collection from Front of Nasal Cavity

Otsuka Group Acquires ISO 14001 Certification -Reinforcement of group-wide environmental initiatives-

Otsuka Has Filed an Application in Japan for Approval of Difamilast (OPA-15406) as an Atopic Dermatitis Drug

Otsuka's ABILIFY MAINTENA approved for the additional indication of bipolar I disorder in Japan

- Creating a Society that Supports Ongoing Employee Health - Full-scale launch of "Kenko Shacho" community website connecting corporate leaders

Smart Nutrition for New Lifestyles Announcing SOYJOY Green Tea & Macadamia Moist Texture Highlights the Mellow Astringency and Savor of Green Tea

Otsuka Pharmaceutical Supports High School Students in Summer 2020 Supporting events across Japan that are close to their hearts, including alternative athletic competitions

Top-line Results from Global Phase 3 Program of Vadadustat, a Drug Candidate for Treatment of Renal Anemia due to Chronic Kidney Disease in Non-Dialysis Patients

Novartis Pharma and Otsuka to Launch Entresto® Tablets in Japan for Patients with Chronic Heart Failure

Otsuka to Co-market New Diagnostic Test for COVID-19, Quick Navi-COVID 19 Ag-Confirmation of test results in just 15 minutes, and easy-to-read results shown in two contrasting colors-

Otsuka Filed Application in Japan for Approval of Fremanezumab as a Prophylactic Treatment for Migraine

Otsuka announces simultaneous regulatory approvals by U.S. FDA and Health Canada of INQOVI®, an oral hypomethylating agent (HMA) therapy for MDS and CMML

Novartis Pharma obtains manufacturing and marketing approval in Japan for Entresto® tablet as angiotensin receptor neprilysin inhibitor (ARNI) for chronic heart failure

Samsca®approved in Japan for additional indication of hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH)

Otsuka Pharmaceutical and Axcelead Drug Discovery Partners announce joint research in CNS indications

Clinical program for NY-ESO-1/siTCRTM gene therapy candidate receives designation in Japan as Orphan Regenerative Medicine

Japan's MHLW grants Sakigake Designation to comprehensive genomic profiling assay for hematologic malignancies co-developed by Otsuka

Introduction of Set of Heat Disorder-related Teaching Materials: "Get Back That Sweat! Preventing Heat Disorders Together"

Launch of a New Combination Ophthalmic Solution for the Treatment of Glaucoma and Ocular Hypertension, AILAMIDE® Combination Ophthalmic Suspension

Otsuka Announces Positive Top-line Results from Two Phase 3 Studies of Centanafadine for the Treatment of Attention-deficit Hyperactivity Disorder (ADHD) in Adult Patients

Deltyba® (delamanid) approved in Russian Federation for treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB)

Launch of Aspirin/Vonoprazan Fumarate Combination Tablets: "Cabpirin® Combination Tablets"

Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis

Otsuka Pharmaceutical to use CO2-free electricity at all plants in Japan (PDF: 96.4 KB)

Research on the Relationship Between Hair Problems and Capacity to Produce Equol

Otsuka Enters into Licensing Agreement in Japan for Bempedoic Acid, a Treatment for Hypercholesterolemia

Otsuka to Introduce QuickNaviTM-Adeno2, an Adenovirus Quick Measurement Kit- Faster and clearer test results with two contrasting colors -

Development of the first comprehensive genomic profiling assay for hematologic malignancies in Japan- Consortium of major Japanese hospitals and Otsuka Pharmaceutical start a project to evaluate its clinical utility -

Otsuka Announces Top-line Results from Two Phase 3 Studies in Japan for Atopic Dermatitis Drug Candidate Difamilast (OPA-15406)

Otsuka's Busulfex Receives Additional Indication in Japan as a Conditioning regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Malignant Lymphoma

Cabpirin® Combination Tablet Receives Regulatory Approval in Japan for Treatment of Acid-related Diseases in Patients Needing Low-dose Aspirin

Dietary Education App "SketchCook" Recognized with Ministry of Education, Culture, Sports, Science and Technology（MEXT） "Award for Companies Promoting Experience-based Learning Activities for Youth 2019"

Newly published findings on inhibitory effect of near-infrared (IRA) radiation on human epidermal cell proliferation and potential mechanisms

Otsuka Pharmaceutical Reappointments and New Appointments of Board Members and Statutory Auditors (PDF: 57.4 KB)

Introducing InnerSignal Rejuvenate ONE－All-in-One Skin Care Product with Time-Lapse Penetration Combines Lightening and Three Basic Skin Care Functions－

Otsuka enters into co-promotion agreement for angiotensin receptor neprilysin inhibitor (ARNI) LCZ696 in Japan

First-of-its-kind global collaboration launched to develop transformative treatment regimens for tuberculosis

Otsuka Pharmaceutical Establishes Subsidiary in Malaysia

Introducing New UL·OS Face & Body Sheet A single sheet provides convenient facial and body care

Launch of "Health Support Plus" Service to manage workforce health based on desknet's NEO groupware

Whole soy nutrition bar delivers the same satisfying crunchy texture with a significant reduction in sugars SOYJOY Peanuts Renewal Launch

Otsuka Pharmaceutical and the Japan Kidney Association Form Collaborative Agreement -Aim to identify practical uses of basic research in the kidney field-

Otsuka announces that subsidiary Astex Pharmaceuticals' NDA for ASTX727 (oral C-DEC), for the treatment of MDS and CMML, has been accepted for priority review by the U.S. FDA

Tokyo Marathon 2020 - Connecting With the World Otsuka Pharmaceutical to be an Official Partner for 14th consecutive year

Otsuka Pharmaceutical Establishes Health Beverage Subsidiary in Mexico

Otsuka announces positive top-line results from clinical trials in Japan offremanezumab as a prophylactic treatment for migraine

Otsuka Pharmaceutical Awarded Grand Prize in Tokyo Metropolitan Government Women's Participation Awards for First Year of the Reiwa Era

Otsuka enters multi-project drug discovery collaboration with PhoreMost Limited

Otsuka Pharmaceutical Signs On as "B. League Supporting Company"
-To cooperate with physical conditioning and regional healthcare-related initiatives-

Quick Navi^TM Rapid Diagnostic Test in Japan Now Supports Simultaneous Testing for Influenza and COVID-19 Through Collection of a Single Testing Sample

Positive Top-Line Results in Phase 3 Trial of OPC-61815, a V₂ -Receptor Antagonist for the Treatment of Cardiac Edema

Quick Navi^TM-COVID 19 Ag Rapid Diagnostic Test in Japan Now Enables Test Sample Collection from Front of Nasal Cavity

Otsuka Pharmaceutical Supports High School Students in Summer 2020
Supporting events across Japan that are close to their hearts, including alternative athletic competitions

Novartis Pharma and Otsuka to Launch Entresto^® Tablets in Japan for Patients with Chronic Heart Failure

Otsuka announces simultaneous regulatory approvals by U.S. FDA and Health Canada of INQOVI^®, an oral hypomethylating agent (HMA) therapy for MDS and CMML

Novartis Pharma obtains manufacturing and marketing approval in Japan for Entresto^® tablet as angiotensin receptor neprilysin inhibitor (ARNI) for chronic heart failure

Samsca^®approved in Japan for additional indication of hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH)

Clinical program for NY-ESO-1/siTCR^TM gene therapy candidate receives designation in Japan as Orphan Regenerative Medicine

Launch of a New Combination Ophthalmic Solution for the Treatment of Glaucoma and Ocular Hypertension, AILAMIDE^® Combination Ophthalmic Suspension

Deltyba^® (delamanid) approved in Russian Federation for treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB)

Launch of Aspirin/Vonoprazan Fumarate Combination Tablets: "Cabpirin_® Combination Tablets"

Otsuka to Introduce QuickNavi^TM-Adeno2, an Adenovirus Quick Measurement Kit- Faster and clearer test results with two contrasting colors -

Cabpirin_® Combination Tablet Receives Regulatory Approval in Japan for Treatment of Acid-related Diseases in Patients Needing Low-dose Aspirin

Dietary Education App "SketchCook"
Recognized with Ministry of Education, Culture, Sports, Science and Technology（MEXT）
"Award for Companies Promoting Experience-based Learning Activities for Youth 2019"

Launch of "Health Support Plus"
Service to manage workforce health based on desknet's NEO groupware

Whole soy nutrition bar delivers the same satisfying crunchy texture with a significant reduction in sugars
SOYJOY Peanuts Renewal Launch